Newsroom
Press releases
- 05/02/2025
Serac Healthcare Announces Successful FDA End of Phase II Meeting for Endometriosis Imaging Agent - Positive Feedback on Phase III Trial Design -
Serac Healthcare Limited today announced positive feedback from its End of Phase II Meeting with the US Food and Drug Administration (FDA) for the development of 99mTc-maraciclatide as a diagnostic agent for use with single-photon emission computed tomography (SPECT-CT) for the visualisation and diagnosis of superficial peritoneal endometriosis (SPE) in women aged 16 years of age and older.
- 14/01/2025
DETECT abstract accepted at World Congress on Endometriosis 2025
An abstract on the “Detecting Endometriosis integrins using technetium-99m” (DETECT) imaging study, has been accepted for oral presentation at the prestigious 16th World Congress on Endometriosis taking place from 21-24 May in Sydney, Australia.
- 23/10/2024
DETECT Endometriosis Imaging Study Presented at EANM’24
Serac Healthcare Limited announces that its clinical partner, the Nuffield Department of Women’s and Reproductive Health at the University of Oxford, gave a presentation on the “Detecting Endometriosis expressed integrins using technetium-99m” (DETECT) imaging study at the European Association of Nuclear Medicine (EANM) annual congress taking place from 19-23 October in Hamburg, Germany
- 09/10/2024
Poster Presented at MICCAI on AI Joint Classification of Images using ⁹⁹ᵐTc-Maraciclatide
A poster was presented today at the annual conference of the Medical Image Computing and Computer Assisted Intervention Society (MICCAI) taking place from 6-10 October in Marrakesh, Morocco. The poster illustrates the latest methodology used in the ongoing research collaboration with King’s College London to develop AI tools to help clinicians read and interpret scans using 99mTc-maraciclatide.
- 08/10/2024
EANM DETECT Abstract Published and Presentation Details
An abstract on preliminary data from the DETECT “Detecting Endometriosis expressed integrins using technetium-99m” imaging study, has been published ahead of the upcoming congress of the European Association of Nuclear Medicine (EANM).
- 10/09/2024
Phase II PREDICT-ILD Imaging Study Commences in Interstitial Lung Disease
Serac Healthcare Limited and the University of Exeter today announce that the first patient has been scanned with a novel molecular SPECT imaging agent 99mTc-maraciclatide in a Phase II study titled ‘PRospective Evaluation of Interstitial Lung Disease progression with quantitative CT (PREDICT-ILD)’.
Events
Updates on our research programmes will be presented at the following conferences:
